Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
high-fat diet plus Streptozotocin | decrease | disulfide-bond A oxidoreductase-like protein (DsbA-L) in the kidneys | diabetic mice | - | decreased expression levels | #1 |
high-fat diet plus Streptozotocin | increase | adipocyte differentiation-related protein | diabetic mice | - | increased expression | #2 |
high-fat diet plus Streptozotocin | neutral | collagen I, fibronectin, phosphorylated 5'AMP-activated kinase (p-AMPK), adipose triglyceride lipase (p-ATGL), and HMG-CoA reductase (p-HMGCR) | diabetic mice | - | abnormal levels | #3 |
high-fat diet plus Streptozotocin | increase | lipid droplets in the kidney | diabetic mice | - | deposition | #4 |
DsbA-L knockout | increase | alterations (lipid droplet deposition, protein expression changes) | diabetic mice | - | more pronounced | #5 |
overexpression of DsbA-L | decrease | high glucose-induced intracellular lipid droplet deposition | human proximal tubular cell line | - | ameliorated | #6 |
DsbA-L siRNA | increase | lipid droplet deposition | human proximal tubular cell line | - | aggravated | #7 |
DsbA-L siRNA | decrease | levels of p-AMPK, p-ATGL, and p-HMGCR | human proximal tubular cell line | - | reduced | #8 |
high glucose and palmitic acid treatment | increase | expression of interleukin-1β and interleukin-18 | human proximal tubular cell line | - | enhanced | #9 |
DsbA-L siRNA | increase | enhancements (expression of interleukin-1β and interleukin-18) | human proximal tubular cell line | - | further increased | #10 |
co-treatment with an AMPK activator | decrease | enhancements (expression of interleukin-1β and interleukin-18) | human proximal tubular cell line | - | alleviated | #11 |
DsbA-L expression | decrease | EFD and tubular damage | patients with diabetic nephropathy | - | negatively correlated | #12 |
Ectopic fat deposition (EFD) in the kidney has been shown to play a causal role in diabetic nephropathy; however, the mechanism underlying EFD remains elusive. By transcriptome analysis, we found decreased expression levels of disulfide-bond A oxidoreductase-like protein (DsbA-L) in the kidneys of diabetic mice (induced by high-fat diet plus Streptozotocin) compared with control mice. Increased expression of adipocyte differentiation-related protein and abnormal levels of collagen I, fibronectin, and phosphorylated 5'AMP-activated kinase (p-AMPK), adipose triglyceride lipase (p-ATGL), and HMG-CoA reductase (p-HMGCR) were also observed in diabetic mice. These alterations were accompanied by deposition of lipid droplets in the kidney, and were more pronounced in diabetic DsbA-L knockout mice. In vitro, overexpression of DsbA-L ameliorated high glucose-induced intracellular lipid droplet deposition in a human proximal tubular cell line, and DsbA-L siRNA aggravated lipid droplet deposition and reduced the levels of p-AMPK, p-ATGL, and p-HMGCR. High glucose and palmitic acid treatment enhanced the expression of interleukin-1β and interleukin-18; these enhancements were further increased after treatment with DsbA-L siRNA but alleviated by co-treatment with an AMPK activator. In kidney biopsy tissue from patients with diabetic nephropathy, DsbA-L expression was negatively correlated with EFD and tubular damage. Collectively, these results suggest that DsbA-L has a protective role against EFD and lipid-related kidney damage in diabetic nephropathy. Activation of the AMPK pathway is a potential mechanism underlying DsbA-L action in the kidney.